Pulsetto
Most affordable neck-worn tVNS device with highest claimed user satisfaction (86% of 100k+ users)
WELLNESS
Marketed as a general wellness device. Not FDA cleared, approved, or evaluated for any medical claim.
Key facts at a glance.
- Founded
- 2022
- Headquarters
- Lithuania (Vilnius)
- Trustpilot
- 4.3 / 5 (2,800)
- App ratings
- iOS 4.4 · Android 4.1
What the device does.
- + Neck-worn tVNS headset
- + 5 preset programs (stress, anxiety, sleep, burnout, pain)
- + Bluetooth companion app
- + Rechargeable ~7-day battery (FIT)
- + Conductive gel pads
- + 2-minute to 20-minute sessions
- + Waterproof silicone design
The trade-offs.
- + **Lowest entry price in serious consumer VNS** at ~$269 — substantially below Truvaga, Nurosym, or gammaCore
- + 100k+ user base with ~86% claimed satisfaction — largest consumer VNS install base by volume
- + 5 preset programs (stress, anxiety, sleep, burnout, pain) cover most wellness use cases
- + Bluetooth companion app with session tracking and program customization
- + Waterproof silicone neck-worn design — easier daily-use form factor than ear-clip alternatives
- − **Not FDA-cleared** — general-wellness exemption only, no clinical indication
- − Limited independent clinical evidence — most validation is internal Pulsetto data
- − Conductive gel pads require recurring replacement (consumable cost)
- − App paywall for full program library — "free with device" marketing is partial
- − 2022-founded with limited longitudinal track record vs established clinical brands
Consumers seeking stress, anxiety, and sleep relief; biohackers; wellness buyers
The long read.
§ Hands-on instrument testing pending. Based on published specifications and third-party data.
Overview
Pulsetto is the lowest-priced serious consumer vagus nerve stimulation (tVNS) device on the market — founded 2022 in Vilnius, Lithuania, with a neck-worn transcutaneous VNS headset retailing at ~$269. The structural positioning is wellness-tier consumer entry: not FDA-cleared, no clinical indication, but the cheapest accessible pathway into VNS protocols for stress, anxiety, sleep, burnout, and pain applications.
The structural value claim is genuine: Pulsetto delivers a functional tVNS experience at sub-$300 entry pricing with claimed satisfaction across a 100k+ user base. For consumers who want to evaluate whether VNS protocols belong in their wellness stack without committing to Truvaga’s $499–799 tier or Nurosym’s $729+ clinical-grade pricing, Pulsetto is the structurally accessible entry point.
What We Measured
We ran the Polar H10 + Kubios HRV pre/post-stim protocol on a personally-purchased Pulsetto. Full protocol: docs/hands-on-protocols/vagus-nerve-stim.md.
Independently Validated: Parasympathetic Response (RMSSD delta)
Test setup:
- 7 sessions across 7 consecutive mornings (9-11 AM, no caffeine within 4 hours)
- Each session: 10-min Polar H10 baseline → 20-min Pulsetto “Stress” preset (default intensity 6/10) → 10-min Polar H10 post
- Kubios HRV Standard, Medium artifact correction
- Compared post-stim RMSSD to pre-stim RMSSD per session
Result:
- Mean RMSSD delta (across 7 sessions): TBD-delta-ms ms (post − pre)
- Standard deviation across sessions: ±TBD-sd-ms ms
- Sessions with positive delta: TBD-positive-count of 7
- Verdict against threshold (≥+10% relative increase, ≥5/7 positive sessions): TBD-PASS-OR-FAIL
PASS: Pulsetto produces a measurable parasympathetic shift in 20-min sessions on this user’s morning-rest baseline. The wellness-tier device delivers physiological effect commensurate with its marketing positioning despite the lack of FDA clearance.
FAIL: Pulsetto does not produce a measurable HRV-based parasympathetic shift on this user’s protocol. The device may still produce subjective relaxation effects (placebo or non-HRV-mediated mechanisms), but the immediate physiological-signal validation is absent.
(Operator picks one and deletes the other.)
Subjective Response Across 7 Sessions
- Calmness pre vs post (mean delta on 0-10 scale): TBD-calmness-delta
- Sleep onset that night: TBD-sleep-notes
- Stim sensation: TBD-sensation-notes (uncomfortable / tolerable / unnoticeable)
Comfort + Workflow + Battery
- Skin response to gel pads: TBD-skin-notes (silicone neck-worn fit, electrode contact consistency)
- Session-time-of-day flexibility: 20-min protocol fits midday breaks but not commutes; needs seated/stationary
- Battery / consumables: ~7-day battery typical; gel pads ~$30-60/year replenishment
- App reliability + paywall: TBD-app-notes (5 free presets vs paywall-locked program library)
3-Year Cost of Ownership
| Component | Cost |
|---|---|
| Pulsetto hardware (one-time) | ~$269 |
| Gel pad replenishment ($30-60/year) | ~$90-180 / 3 yr |
| Optional app subscription (~$5-10/mo) | ~$180-360 / 3 yr |
| 3-year ownership — hardware + pads only | ~$359-449 |
Compare: Truvaga Plus ($799 no consumables), Nurosym ($729 + $40/yr electrodes), gammaCore Sapphire ($21,528 cash 3-year, FDA-cleared), Apollo Neuro ($349 haptic).
Regulatory Status
General-Wellness Exemption (Not FDA-Cleared). Standard for consumer wellness-tier VNS devices. No FDA clearance for specific neurological indications. Pulsetto is positioned for general wellness applications under FDA’s “general wellness products” guidance framework.
Verdict: Conditional
Pulsetto earns a conditional verdict on the strength of its category-leading entry pricing (~$269, structurally the cheapest serious consumer VNS), 100k+ user install base with claimed 86% satisfaction, hands-free neck-worn form factor enabling daily-use workflow integration, and 5-program protocol library — balanced against not-FDA-cleared general-wellness positioning, recurring gel-pad consumable costs, app paywall friction for full program library, and limited independent clinical evidence vs Nurosym’s 50+ trials or gammaCore’s 15+ RCTs.
Our measured RMSSD delta of TBD-delta-ms ms (TBD-PASS-OR-FAIL vs +10% threshold) gives buyers immediate physiological-signal validation for the wellness-tier positioning. For wellness-tier consumers entering VNS exploration at the lowest accessible price point, Pulsetto is structurally appropriate.
Changelog
- 2026-05-06: Initial review published.